D. E. Shaw & Co., Inc. Autolus Therapeutics PLC Transaction History
D. E. Shaw & Co., Inc.
- $107 Billion
- Q3 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 91,687 shares of AUTL stock, worth $216,381. This represents 0.0% of its overall portfolio holdings.
Number of Shares
91,687Holding current value
$216,381% of portfolio
0.0%Shares
6 transactions
Others Institutions Holding AUTL
# of Institutions
104Shares Held
163MCall Options Held
2.8KPut Options Held
13.4K-
Wellington Management Group LLP Boston, MA24.2MShares$57.2 Million0.02% of portfolio
-
Blackstone Inc New York, NY20.5MShares$48.3 Million0.35% of portfolio
-
Syncona Portfolio LTD Guernsey, Channel Islands, X018.6MShares$43.8 Million83.42% of portfolio
-
Deep Track Capital, LP Greenwich, CT15.3MShares$36 Million2.04% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.3MShares$29.1 Million0.67% of portfolio
About Autolus Therapeutics plc
- Ticker AUTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 90,909,800
- Market Cap $215M
- Description
- Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...